The purpose of this study is to evaluate the safety and efficacy of ocular iontophoresis with dexamethasone phosphate ophthalmic solution EGP-437 using the EyeGate II Drug Delivery System (EGDS) compared to prednisolone acetate ophthalmic suspension (1%) in patients with non-infectious anterior segment uveitis.
Dr. Vincente Diaz, Uveitis Specialist and Principal Investigator of this study can determine if you are eligible.
You may qualify if you:
- are Male or female, age 12 to 85 years with a diagnosis of non-infectious anterior segment uveitis defined as an anterior chamber cell count of greater than or equal to 11 cells
- Other protocol-defined inclusion/exclusion criteria may apply
This is a fully funded trial. All research related procedures and medication will be at no cost to the patient.